Caplin Point Laboratories (524742) Q1 24/25 earnings summary

Executive summary

• Celebrated 30 years as a public-listed company, highlighting significant growth in revenue, PAT, and market cap over the past decade.

• Q1 FY25 consolidated revenue from operations rose 16.1% year-over-year to ₹458.96 Cr, with PAT up 19.8% to ₹124.92 Cr, driven by strong growth in both Latin America and the US markets.

• Emphasized a unique business model focused on cash flow, profits, and serving underserved markets, especially in Latin America and the U.S.

• Continued expansion into regulated markets, including the US, Canada, Australia, Mexico, and Brazil.

• Focused on cash flow and bottom-line growth, with branded generics and specialty products driving profitability.

Financial highlights

• Q1 FY25 revenue from operations: ₹458.96 Cr, up 16.1% YoY; PAT: ₹124.92 Cr, up 19.8% YoY; gross margin: 59.6%.

• EBITDA: ₹170.37 Cr, up 23% YoY; EBITDA margin: 35.7%.

• Free cash flow for the quarter was ₹59 Cr; cash reserves as of June 2024 were ₹969.2 Cr.

• FY24 revenue: ₹1,694 Cr, up 16% YoY; PAT: ₹461 Cr, up 22% YoY.

• Basic EPS: ₹16.32, up 19.8% YoY.

Outlook and guidance

• Oncology injectables facility expected to be completed by March 2025; further expansion in U.S. and Latin America planned.

• Targeting $100 million sales in Caplin Steriles by FY27 remains on track.

• Plans to launch 35 products in the US in the next 12 months, with first launches by October 2024.

• Targeting breakeven revenue for the new oncology site in LatAm within 12 months.

• Ongoing expansion into new geographies and product segments, supported by internal accruals.